Erhan Keleş

(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase

Denise Rageot, Thomas Bohnacker, Erhan Keleş et al. · Journal of Medicinal Chemistry · 2019 · 54 citations · Full text

Compound 6, Brain Penetration, Cellular Pharmacology +25

Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas

Sung Hugh Choi, Daniel W. Stuckey, Sara Pignatta et al. · Clinical Cancer Research · 2017 · 53 citations · Full text

Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα

Chiara Borsari, Erhan Keleş, Jacob A. McPhail et al. · Journal of the American Chemical Society · 2022 · 51 citations · Full text

Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety

Chiara Borsari, Denise Rageot, Florent Beaufils et al. · ACS Medicinal Chemistry Letters · 2019 · 39 citations · Full text

4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders

Chiara Borsari, Erhan Keleş, Denise Rageot et al. · Journal of Medicinal Chemistry · 2020 · 21 citations · Full text